AAD 2024

by Deileta Kamhunga An artificial intelligence-based psoriasis severity assessment model may be a promising alternative for dermatologists’ assessments, according to a real-world study. Psoriasis is a chronic, immune-mediated skin disease. The therapeutic management plan for psoriasis is established according to the degree of disease severity. The Psoriasis Area and Severity Index (PASI) is currently the...

CT-P43 demonstrated efficacy and safety comparable to originator ustekinumab in treating moderate-to-severe plaque psoriasis in a phase III trial. Plaque psoriasis is a chronic inflammatory disease with an estimated prevalence of ≥1.5% in Australasia, Western and Central Europe, and North America. Ustekinumab is a monoclonal antibody approved for treating moderate-to-severe plaque psoriasis.  A randomized, active-controlled,...